What is Aether?
Headquartered in the United States and led by CEO and Founder Pavle Jeremi, Aether operates at the intersection of artificial intelligence and biotechnology. The firm's core competency lies in its Protein Function Model, a sophisticated computational engine designed to generate proteins with specific, high-impact functions for real-world applications. Unlike traditional discovery methods, Aether utilizes an entirely proprietary dataset, meticulously curated through in-house high-throughput screening and innovative assay development. This vertical integration allows the company to maintain a competitive edge in the rapidly evolving landscape of synthetic biology and therapeutic development, positioning it as a critical player in the future of molecular design.
How much funding has Aether raised?
Aether has raised a total of $64.2M across 3 funding rounds:
Debt
$150K
Series A
$49M
Other Financing Round
$15M
Debt (2020): $150K with participation from PPP
Series A (2023): $49M led by Jay Zaveri and Trevor Zimmerman
Other Financing Round (2025): $15M supported by Tribe Management, Henkel Ventures, 4DX Ventures, and Shrug Capital
Key Investors in Aether
Tribe Management
Tribe Capital is a $1.8B AUM venture capital firm based in Menlo Park, California, established in June 2018. The firm specializes in leveraging AI and data science to strategically deploy capital into N-of-1 companies.
Henkel Ventures
Henkel Ventures is the Corporate Venture Capital arm of Henkel, focusing on providing funding and strategic partnerships to early-stage startups with a focus on sustainability and digitalization.
4DX Ventures
4DX Ventures is an early-stage venture capital firm established in 2017, primarily focused on supporting high-growth startups within the African market.
What's next for Aether?
With this major strategic investment, Aether is well-positioned to scale its computational infrastructure and expand its pipeline of novel protein candidates. The company's roadmap likely involves deepening its integration of AI-driven discovery into commercial-scale applications, potentially targeting high-value sectors such as pharmaceuticals, sustainable materials, and industrial biotechnology. By leveraging the expertise of its diverse investor base, Aether is poised to transition from a research-heavy entity into a commercial powerhouse, focusing on the validation of its protein designs in real-world environments. The focus remains on maintaining the integrity of its proprietary dataset while exploring strategic partnerships that can translate its computational breakthroughs into tangible, market-ready solutions.
See full Aether company page
